{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:59:22Z","timestamp":1793239162054,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1014263","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000}}],"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS132022"],"award-info":[{"award-number":["R01 NS132022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["COBRE P20 GM152335"],"award-info":[{"award-number":["COBRE P20 GM152335"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Prion Alliance","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gate Bio"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>PrP lowering is effective against prion disease in animal models and is being tested clinically. Therapies in the current pipeline lower PrP production, leaving pre-existing PrP to be cleared according to its own half-life. We hypothesized that PrP\u2019s half-life may be a rate-limiting factor for the time to effect of PrP-lowering drugs, and one reason why late treatment of prion-infected mice is not as effective as early treatment. Using isotopically labeled diet with targeted mass spectrometry, as well as antisense oligonucleotide treatment followed by timed PrP measurement, we estimate a half-life of 5\u20136 days for PrP in the brain. PrP turnover is not affected by over- or under-expression. Mouse PrP and human PrP have similar turnover rates measured in wild-type or humanized knock-in mice. CSF PrP appears to mirror brain PrP in real time in rats. PrP in the colon is readily quantifiable and has a half-life just slightly shorter than in brain. An under-expressed pathogenic mutant PrP, corresponding to D178N in humans, exhibits an accelerated turnover rate. Our data may inform the design of both preclinical and clinical studies of PrP-lowering drugs.<\/jats:p>","DOI":"10.1371\/journal.ppat.1014263","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:33:41Z","timestamp":1779816821000},"page":"e1014263","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["PrP turnover in vivo and the time to effect of prion disease therapeutics"],"prefix":"10.1371","volume":"22","author":[{"given":"Taylor L.","family":"Corridon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"O\u2019Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Seerley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Laversenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita G.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona E.","family":"Serack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Basit","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrick","family":"DeSouza-Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker S.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Reidenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah E.","family":"Cabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Vallabh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Grindeland Panter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Oberbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien T.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-1608","authenticated-orcid":true,"given":"Eric Vallabh","family":"Minikel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"19","key":"ppat.1014263.ref001","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","article-title":"Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints","volume":"48","author":"EV Minikel","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"ppat.1014263.ref002","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131175","article-title":"Antisense oligonucleotides extend survival of prion-infected mice","volume":"5","author":"GJ Raymond","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"ppat.1014263.ref003","article-title":"Intracerebral infusion of antisense oligonucleotides into prion-infected mice","volume":"1","author":"K Nazor Friberg","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"key":"ppat.1014263.ref004","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"SB Prusiner","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ppat.1014263.ref005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1474-4422(19)30403-X","article-title":"Towards a treatment for genetic prion disease: trials and biomarkers","volume":"19","author":"SM Vallabh","year":"2020","journal-title":"Lancet Neurol"},{"issue":"6689","key":"ppat.1014263.ref006","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1126\/science.adp3043","article-title":"Foiling deadly prions","volume":"383","author":"M Wadman","year":"2024","journal-title":"Science"},{"key":"ppat.1014263.ref007","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/brain\/awh249","article-title":"Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies","volume":"127","author":"M Pocchiari","year":"2004","journal-title":"Brain"},{"issue":"23","key":"ppat.1014263.ref008","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","article-title":"Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease","volume":"81","author":"MD Geschwind","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"ppat.1014263.ref009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","author":"S Ha\u00efk","year":"2014","journal-title":"Lancet Neurol"},{"issue":"17","key":"ppat.1014263.ref010","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"H Wu","year":"2004","journal-title":"J Biol Chem"},{"issue":"1","key":"ppat.1014263.ref011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom10010001","article-title":"Characterization of the prion protein binding properties of antisense oligonucleotides","volume":"10","author":"AG Reidenbach","year":"2019","journal-title":"Biomolecules"},{"issue":"1","key":"ppat.1014263.ref012","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1128\/jvi.63.1.175-181.1989","article-title":"Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells","volume":"63","author":"B Caughey","year":"1989","journal-title":"J Virol"},{"issue":"3","key":"ppat.1014263.ref013","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1083\/jcb.110.3.743","article-title":"Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells","volume":"110","author":"DR Borchelt","year":"1990","journal-title":"J Cell Biol"},{"key":"ppat.1014263.ref014","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1099\/vir.0.80947-0","article-title":"Prion clearance in bigenic mice","volume":"86","author":"JG Safar","year":"2005","journal-title":"J Gen Virol"},{"issue":"32","key":"ppat.1014263.ref015","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1006551107","article-title":"Analysis of proteome dynamics in the mouse brain","volume":"107","author":"JC Price","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ppat.1014263.ref016","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1038\/s41467-018-06519-0","article-title":"Precisely measured protein lifetimes in the mouse brain reveal differences across tissues and subcellular fractions","volume":"9","author":"EF Fornasiero","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"ppat.1014263.ref017","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156532","article-title":"Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS","volume":"7","author":"MA Mortberg","year":"2022","journal-title":"JCI Insight"},{"issue":"7","key":"ppat.1014263.ref018","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1172\/JCI80705","article-title":"In vivo kinetic approach reveals slow SOD1 turnover in the CNS","volume":"125","author":"MJ Crisp","year":"2015","journal-title":"J Clin Invest"},{"issue":"1","key":"ppat.1014263.ref019","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-020-01608-8","article-title":"Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease","volume":"18","author":"SM Vallabh","year":"2020","journal-title":"BMC Med"},{"issue":"2","key":"ppat.1014263.ref020","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209506","article-title":"Fluid biomarkers in individuals at risk for genetic prion disease up to disease conversion","volume":"103","author":"SM Vallabh","year":"2024","journal-title":"Neurology"},{"issue":"6509","key":"ppat.1014263.ref021","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues","volume":"369","author":"GTEx Consortium","year":"2020","journal-title":"Science"},{"key":"ppat.1014263.ref022","doi-asserted-by":"crossref","first-page":"170185","DOI":"10.1038\/sdata.2017.185","article-title":"An RNA-Seq atlas of gene expression in mouse and rat normal tissues","volume":"4","author":"JF S\u00f6llner","year":"2017","journal-title":"Sci Data"},{"issue":"12","key":"ppat.1014263.ref023","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1074\/mcp.RA119.001702","article-title":"Domain-specific quantification of prion protein in cerebrospinal fluid by targeted mass spectrometry","volume":"18","author":"EV Minikel","year":"2019","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"ppat.1014263.ref024","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0092-8674(87)90134-6","article-title":"Distinct prion proteins in short and long scrapie incubation period mice","volume":"51","author":"D Westaway","year":"1987","journal-title":"Cell"},{"key":"ppat.1014263.ref025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.20151610","article-title":"Strictly co-isogenic C57BL\/6J-Prnp-\/- mice: a rigorous resource for prion science","volume":"213","author":"M Nuvolone","year":"2016","journal-title":"J Exp Med"},{"issue":"8","key":"ppat.1014263.ref026","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag287","article-title":"Divalent siRNA for prion disease","volume":"54","author":"JE Gentile","year":"2026","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"ppat.1014263.ref027","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/j.1460-2075.1996.tb00467.x","article-title":"Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie","volume":"15","author":"M Fischer","year":"1996","journal-title":"EMBO J"},{"issue":"4","key":"ppat.1014263.ref028","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.neuron.2009.07.026","article-title":"Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice","volume":"63","author":"WS Jackson","year":"2009","journal-title":"Neuron"},{"issue":"1","key":"ppat.1014263.ref029","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/14789450.3.1.97","article-title":"Protein turnover on the scale of the proteome","volume":"3","author":"MK Doherty","year":"2006","journal-title":"Expert Rev Proteomics"},{"issue":"12","key":"ppat.1014263.ref030","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1074\/mcp.O112.022186","article-title":"Proteome dynamics: revisiting turnover with a global perspective","volume":"11","author":"AJ Claydon","year":"2012","journal-title":"Mol Cell Proteomics"},{"issue":"14","key":"ppat.1014263.ref031","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1093\/nar\/gkad371","article-title":"A single-cell map of antisense oligonucleotide activity in the brain","volume":"51","author":"MA Mortberg","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"ppat.1014263.ref032","unstructured":"Freier SM, Bui H-H, Zhao H. Compounds and methods for reducing prion expression. WO2020106996A1; 2020. Available from: https:\/\/patents.google.com\/patent\/WO2020106996A1\/en"},{"issue":"16","key":"ppat.1014263.ref033","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1073\/pnas.1901947116","article-title":"Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development","volume":"116","author":"SM Vallabh","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ppat.1014263.ref034","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"P Jafar-Nejad","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"ppat.1014263.ref035","doi-asserted-by":"crossref","first-page":"12661","DOI":"10.1074\/jbc.271.21.12661","article-title":"Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein","volume":"271","author":"RB Petersen","year":"1996","journal-title":"J Biol Chem"},{"issue":"21","key":"ppat.1014263.ref036","doi-asserted-by":"crossref","first-page":"12580","DOI":"10.1073\/pnas.95.21.12580","article-title":"Doxycycline control of prion protein transgene expression modulates prion disease in mice","volume":"95","author":"P Tremblay","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ppat.1014263.ref037","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1021\/bi00055a003","article-title":"Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites","volume":"32","author":"DA Harris","year":"1993","journal-title":"Biochemistry"},{"issue":"32","key":"ppat.1014263.ref038","doi-asserted-by":"crossref","first-page":"19173","DOI":"10.1074\/jbc.270.32.19173","article-title":"Truncated forms of the human prion protein in normal brain and in prion diseases","volume":"270","author":"SG Chen","year":"1995","journal-title":"J Biol Chem"},{"issue":"2","key":"ppat.1014263.ref039","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI72241","article-title":"Prion disease tempo determined by host-dependent substrate reduction","volume":"124","author":"CE Mays","year":"2014","journal-title":"J Clin Invest"},{"issue":"20","key":"ppat.1014263.ref040","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1056\/NEJMoa1214747","article-title":"A novel prion disease associated with diarrhea and autonomic neuropathy","volume":"369","author":"S Mead","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"ppat.1014263.ref041","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrneurol.2014.263","article-title":"A new prion disease: relationship with central and peripheral amyloidoses","volume":"11","author":"S Mead","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"322","key":"ppat.1014263.ref042","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5169","article-title":"Quantifying prion disease penetrance using large population control cohorts","volume":"8","author":"EV Minikel","year":"2016","journal-title":"Sci Transl Med"},{"key":"ppat.1014263.ref043","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01672-22","article-title":"Therapeutic trial of anle138b in mouse models of genetic prion disease","volume":"97","author":"SM Vallabh","year":"2023","journal-title":"J Virol"},{"issue":"36","key":"ppat.1014263.ref044","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1073\/pnas.1312006110","article-title":"Profoundly different prion diseases in knock-in mice carrying single PrP codon substitutions associated with human diseases","volume":"110","author":"WS Jackson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"ppat.1014263.ref045","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/nbt.2959","article-title":"Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping","volume":"32","author":"PJP de Vree","year":"2014","journal-title":"Nat Biotechnol"},{"key":"ppat.1014263.ref046","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4939-7244-9_14","article-title":"RT-QuIC assays for prion disease detection and diagnostics","volume":"1658","author":"CD Orr\u00f9","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"39","key":"ppat.1014263.ref047","doi-asserted-by":"crossref","first-page":"13516","DOI":"10.1074\/jbc.RA120.014905","article-title":"Multimodal small-molecule screening for human prion protein binders","volume":"295","author":"AG Reidenbach","year":"2020","journal-title":"J Biol Chem"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1014263","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1014263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:49:55Z","timestamp":1780076995000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1014263"}},"subtitle":[],"editor":[{"given":"Jason C","family":"Bartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1014263","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}